ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

In The States: Illinois, Virginia approve Legislation Mandating Coverage of Care In Cancer Clinical Trials

June 4, 1999

Appropriators Project 1.2% Increase for NIH, Due to Budget Plan

June 20, 1997

NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility

September 7, 1990

In Brief: ACCC Annual Meeting Scheduled March 16-19; Lao to Head Pharmacology At Pittsburgh

January 1, 1988

Dingell Subcommittee Report Next Month To Include New Info

July 1, 1994

In Brief: What’s In A Name? DRCCA Doesn’t Do It; O’Conor Says ICRDB Program Should Consider New Challenges

October 3, 1980